trial

Safety, Blood Levels and Effects of AUT00201

NCTId NCT04158453
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 80 (actual)
Sponsored by Autifony Therapeutics Limited
Primary completion 2020-12-14
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
80 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Quadruple
Start
2019-10-10
Primary completion
2020-12-14
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
AUT00201

Sponsors

Autifony Therapeutics LimitedLead Sponsor

Sites

1 total
London, United Kingdom

Facts & assertions

4 sourced
Enrollment
80
Phase
PHASE1
Primary Completion Date
2020-12-14
Status
COMPLETED
relationships
The graph out of here
drug
AUT00201
drug
lead_sponsor
Autifony Therapeutics Limited
company
indication
Healthy Volunteer
indication
Schizophrenia
indication